{
    "2019-02-15": [
        [
            {
                "time": "2018-03-15",
                "original_text": "U.S. Medicare plans to track CAR-T cancer therapy outcomes",
                "features": {
                    "keywords": [
                        "Medicare",
                        "CAR-T",
                        "cancer",
                        "therapy",
                        "outcomes"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2018-04-10",
                "original_text": "Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Moody's",
                        "ratings",
                        "review"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-20",
                "original_text": "Medicare would cover CAR-T therapies under new CMS proposal",
                "features": {
                    "keywords": [
                        "Medicare",
                        "CAR-T",
                        "therapies",
                        "CMS",
                        "proposal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2019-01-10",
                "original_text": "What Are the Key Growth Drivers for GlaxoSmithKline in 2019?",
                "features": {
                    "keywords": [
                        "Growth",
                        "Drivers",
                        "GlaxoSmithKline"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}